½ÃÀ庸°í¼­
»óǰÄÚµå
1605912

ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® ¸®Æ÷Æ® : ÀӽŠ±â°£º°, ÄÄÆ÷³ÍÆ®º°, ¹æ¹ýº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)

Non-Invasive Prenatal Testing Market Size, Share, Trends, Industry Analysis Report: By Gestation Period, Component, Method, Application, End Use, and Region - Market Forecast, 2025-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 113¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ Á¶»ç ¸®Æ÷Æ®´Â ÇöÀç ½ÃÀå ¿ªÇÐÀÇ »ó¼¼ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí, ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ °üÇÑ ºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

ºñħ½ÀÀû »êÀü °Ë»ç(NIPT)´Â ÀÓ½ÅÇÑ °³ÀÎÀÇ Ç÷¾× »ùÇÃÀ» »ç¿ëÇÏ¿© ´Ù¿îÁõÈıº°ú °°Àº žÆÀÇ Æ¯Á¤ À¯Àü ÁúȯÀ» ¼±º°ÇÏ´Â µ¥ »ç¿ëµÇ´Â ¹æ¹ýÀ» ¸»ÇÕ´Ï´Ù. ÀÌ °Ë»ç´Â »ê¸ðÀÇ Ç÷¾×À» ¼øÈ¯Çϴ žÆÀÇ ÀÛÀº DNA Á¶°¢À» ºÐ¼®ÇÕ´Ï´Ù. ħ½ÀÀûÀÎ ¹æ¹ý¿¡ ºñÇØ Á¤È®ÇÏ°í ¾ÈÀüÇϹǷΠÀÌ¿ëÀÚµé »çÀÌ¿¡¼­ ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

À¯Àü¼º ÁúȯÀÇ Á¶±â ¹ß°ßÀÇ Á߿伺ÀÌ ³ô¾ÆÁö´Â °ÍÀÌ NIPT ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. À¯Àüü ±â¼ú°ú ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ´«ºÎ½Å ¹ßÀüÀÌ NIPT ½ÃÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS) ±â¼úÀÇ ¹ßÀüÀ¸·Î ÅÂ¾Æ DNA ºÐ¼®ÀÇ Á¤È®¼º°ú È¿À²¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº NIPT¸¦ º¸´Ù Àú·ÅÇÏ°í ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ¿Í ȯÀÚµé »çÀÌ¿¡¼­ NIPTÀÇ Ã¤ÅÃÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 5¿ù Illumina, Inc.¿Í Next Generation Genomic Co, Ltd.´Â CE-IVD, NGS ±â¹Ý NIPT Á¢±Ù ¹æ½ÄÀÎ VeriSeq NIPT Solution v2ÀÇ Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ±â¼úÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó NIPTÀÇ ±â´É°ú °¡°ÝÀº ´õ¿í Çâ»óµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºñħ½ÀÀû »êÀü °Ë»ç ½ÃÀåÀº °¡°Ý °æÀï°ú Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ÅëÇÑ ±â¼ú Çõ½Å µîÀÇ Àü·«À¸·Î Ä¡¿­ÇÑ °æÀïÀ» ¹úÀ̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 7¿ù Pacific Biosciences of California, Inc.´Â OmniomeÀÇ Àμö¸¦ ¹ßÇ¥Çß½À´Ï´Ù. À̹ø Àμö¸¦ ÅëÇØ Pacific Biosciences´Â °í°´¿¡°Ô ÇýÅÃÀ» ÁÙ ¼ö Àִ âÀÇÀûÀÎ ¹æ½ÄÀ¸·Î ½ÃÄö¼­ ½ÃÀå ±âȸ¸¦ È®´ëÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, OmniomeÀº Çõ½ÅÀûÀÎ ¹æ¹ýÀ¸·Î °íÁ¤¹Ð ´Ü¼â ¿°±â¼­¿­ ºÐ¼® Ç÷§ÆûÀ» Á¦°øÇÏ¿© ºñħ½ÀÀû »êÀü °Ë»ç, Á¾¾çÇÐ µî ºü¸£°Ô ¼ºÀåÇÏ´Â ÀÓ»ó ¿ëµµ¿¡ ÁøÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ºñħ½ÀÀû »êÀü°Ë»ç, Á¾¾çÇÐ µî ºü¸£°Ô È®´ëµÇ°í ÀÖ´Â ÀÓ»ó ¿ëµµ·ÎÀÇ ÁøÀÔÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ 2024³â 10¿ù, Yourgene Health´Â ÄÝ·Òºñ¾Æ ÃÖÃÊÀÇ ºñħ½ÀÀû »êÀü°Ë»ç(NIPT) ¿öÅ©Ç÷ο츦 Genetix¿¡ ¼³Ä¡Çß½À´Ï´Ù. ÀÌ ¼­ºñ½º´Â ÄÝ·Òºñ¾ÆÀÇ ÀÓ»êºÎ¿¡°Ô ºü¸£°í Á¤È®ÇÑ NIPT °á°ú¸¦ Á¦°øÇÏ¿© ³³±â ¹× ¹è¼Û ¹®Á¦¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

ºñħ½ÀÀû »êÀü °Ë»ç(NIPT) ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¹æ¹ýº° ºÐ¼®¿¡¼­ ¸ðü Ç÷Àå ¹«¼¼Æ÷ DNA °Ë»ç ºÎ¹®ÀÌ 2024³â ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ÁÖ·Î ±âÁ¸ ħ½ÀÀû ¹æ¹ý¿¡ ºñÇØ À§ÇèÀÌ Àû°í Á¤È®µµ°¡ ³ô±â ¶§¹®ÀÔ´Ï´Ù.

¿ëµµº°·Î´Â 21¹ø »ï¿°»öüÁõ(´Ù¿îÁõÈıº), 18¹ø »ï¿°»öüÁõ(¿¡µå¿öÁî ÁõÈıº), 13¹ø »ï¿°»öüÁõ(ÆÄŸ¿ì ÁõÈıº)°ú °°Àº ÀϹÝÀûÀÎ ¿°»öü ÀÌ»ó °ËÃâ¿¡ ÀÖÀ¸¸ç, NIPTÀÇ ¿ªÇÒ·Î ÀÎÇØ 2024³â »ï¿°»öüÁõ ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.

ºÏ¹Ì´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ÀÎÁöµµ, ÷´Ü ±â¼úÀÇ °ß°íÇÑ µµÀÔÀ¸·Î 2024³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº °æÁ¦ ¼ºÀå, ±â¼ú Çõ½Å, Áö¿ªÀû È®Àå, Àü·«Àû ÆÄÆ®³Ê½ÊÀ¸·Î ÀÎÇØ °¡Àå ºü¸¥ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ½ÃÀå ±â¾÷ : Agilent Technologies, Inc., Centogene N.V., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche Ltd.(Ariosa Diagnostics), Agilent Technologies, Inc.(Ariosa Diagnostics), Illumina, Inc., Laboratory Corp. of America Holdings, MedGenome Labs Ltd., Myriad Women's Health, Inc., Natera, Inc., Progenity, Inc., Qiagen, Quest Diagnostics, Inc., Thermo Fisher Scientific, Inc.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå °³¿ä

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå ÀλçÀÌÆ®

  • ¿ëµµ ½º³À¼ô
  • ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀΰú ±âȸ
      • ½ÃÄö½Ì ±â¼ú°ú ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º¿¡¼­ ±â¼ú Áøº¸ÀÇ Áõ°¡
      • Ãâ»ê ¿¬·ÉÀÇ »ó½Â
    • ¾ïÁ¦¿äÀΰú °úÁ¦
      • ºñÀÇÇÐÀû ¹è°æ¿¡ ±â¹ÝÇÑ ¼ºº° ¼±ÅÃÀ» À§ÇÑ NIPT Àû¿ëÀº ÀϺΠ±¹°¡¿¡¼­´Â ±ÝÁöµÇ¾î ÀÖ´Ù.
  • PESTEL ºÐ¼®
  • ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀåÀÇ ¿ëµµ µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå : ÀӽŠ±â°£º°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • 0-12ÁÖ
  • 13-24ÁÖ
  • 25-36ÁÖ

Á¦6Àå ¼¼°èÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ¼Ò¸ðǰ
  • ±â±â
  • ¼ÒÇÁÆ®¿þ¾î
  • ¼­ºñ½º

Á¦7Àå ¼¼°èÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå : ¹æ¹ýº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ¸ðüÇ÷Àå °Ë»ç¿¡¼­ÀÇ Cell-Free DNA
  • ÃÊÀ½ÆÄ ŽÁö
  • »ýÈ­ÇÐ ½ºÅ©¸®´× °Ë»ç
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå : ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ¸ð³ë¼Ò¹Ì
  • Æ®¸®¼Ò¹Ì
  • ¹Ì¼¼°á¼Õ ÁõÈıº
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • Áø´Ü ¼¾ÅÍ
  • º´¿ø°ú Áø·á¼Ò

Á¦10Àå ¼¼°èÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå Æò°¡ : Áö¿ª, 2020-2034³â
  • ºÏ¹Ì
    • ºÏ¹Ì : ÀӽŠ±â°£º°, 2020-2034³â
    • ºÏ¹Ì : ÄÄÆ÷³ÍÆ®º°, 2020-2034³â
    • ºÏ¹Ì : ¹æ¹ýº°, 2020-2034³â
    • ºÏ¹Ì : ¿ëµµº°, 2020-2034³â
    • ºÏ¹Ì : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ : ÀӽŠ±â°£º°, 2020-2034³â
    • À¯·´ : ÄÄÆ÷³ÍÆ®º°, 2020-2034³â
    • À¯·´ : ¹æ¹ýº°, 2020-2034³â
    • À¯·´ : ¿ëµµº°, 2020-2034³â
    • À¯·´ : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÀӽŠ±â°£º°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÄÄÆ÷³ÍÆ®º°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¹æ¹ýº°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¿ëµµº°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
    • Áß±¹
    • Àεµ
    • ¸»·¹À̽þÆ
    • ÀϺ»
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÀӽŠ±â°£º°, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÄÄÆ÷³ÍÆ®º°, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¹æ¹ýº°, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¿ëµµº°, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : ÀӽŠ±â°£º°, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ÄÄÆ÷³ÍÆ®º°, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¹æ¹ýº°, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¿ëµµº°, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦11Àå °æÀï ±¸µµ

  • È®´ë¿Í Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦12Àå ±â¾÷ °³¿ä

  • Agilent Technologies, Inc.
  • Centogene N.V
  • Eurofins LifeCodexx GmbH
  • F;Hoffmann-La Roche Ltd
  • Illumina, Inc
  • Laboratory Corp. of America Holdings
  • MedGenome Labs Ltd
  • Myriad Women's Health, Inc.
  • Natera, Inc.
  • Progenity, Inc.
  • Qiagen
  • Quest Diagnostics, Inc.
  • Thermo Fisher Scientific, Inc.
KSA 25.01.06

The non-invasive prenatal testing market size is expected to reach USD 11.39 billion by 2034, according to a new study by Polaris Market Research. The report "Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, Industry Analysis Report: By Gestation Period (0-12 Weeks, 13-24 Weeks, and 25-36 Weeks), Component, Method, Application, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-invasive prenatal testing (NIPT) refers to a method used to screen for certain genetic conditions in a fetus, such as Down syndrome, using a blood sample from the pregnant individual. This test analyzes small fragments of fetal DNA that are circulating in the maternal blood. It is a preferred option among users for its accuracy and safety compared to invasive methods.

The growing importance of early detection of genetic disorders is a primary driver for the NIPT market. Significant advancements in genomic technology and bioinformatics have propelled the NIPT market. Improvements in next-generation sequencing (NGS) technology have enhanced the accuracy and efficiency of fetal DNA analysis. These technological innovations have led to more affordable and accessible NIPT options, thereby expanding its adoption among healthcare providers and patients. For instance, in May 2021, Illumina, Inc. and Next Generation Genomic Co., Ltd. announced the launch of VeriSeq NIPT Solution v2, a CE-IVD, NGS-based approach to NIPT. As technology continues to evolve, it is expected to improve the capabilities and affordability of NIPT further.

The non-invasive prenatal testing market is driven by intense competition with strategies including price competitiveness and technological innovation with strategic partnerships. For instance, in July 2021, Pacific Biosciences of California, Inc. announced the acquisition of Omniome. With the acquisition, Pacific Biosciences will be able to expand the market opportunity for sequencing in creative ways that benefit customers. Through its innovative methodology, Omniome aims to provide an accurate short-read sequencing platform to enable it to enter rapidly expanding clinical application areas such as non-invasive prenatal testing and oncology.

Additionaly, in October 2024, Yourgene Health installed the first non-invasive prenatal testing (NIPT) workflow in Colombia at Genetix. The service will deliver fast, precise NIPT results for expectant parents in Colombia, serving to reduce turnaround times and delivery problems.

Non-Invasive Prenatal Testing (NIPT) Market Report Highlights

By method analysis, the cell-free DNA in maternal plasma tests segment dominated the market in 2024, mainly attributed to its minimal risk and superior accuracy compared to traditional invasive methods.

By application analysis, the trisomy segment dominated the market in 2024 owing to NIPT's role in detecting common chromosomal abnormalities such as Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).

North America dominated the market in 2024 due to advanced healthcare infrastructure, high awareness levels, and robust adoption of advanced technologies.

Asia Pacific is expected to register the fastest CAGR, owing to economic growth, technological innovation, geographic expansion, and strategic partnerships.

The key market players include Agilent Technologies, Inc.; Centogene N.V.; Eurofins LifeCodexx GmbH; F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics); Illumina, Inc.; Laboratory Corp. of America Holdings; MedGenome Labs Ltd.; Myriad Women's Health, Inc.; Natera, Inc.; Progenity, Inc.; Qiagen; Quest Diagnostics, Inc.; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the non-invasive prenatal testing market report based on gestation period, component, method, application, end use, and region:

By Gestation Period Outlook (Revenue - USD Billion, 2020-2034)

  • 0-12 weeks
  • 13-24 weeks
  • 25-36 weeks

By Component Outlook (Revenue - USD Billion, 2020-2034)

  • Consumables
  • Instruments
  • Software
  • Services

By Method Outlook (Revenue - USD Billion, 2020-2034)

  • Cell-Free DNA in Maternal Plasma Tests
  • Ultrasound Detection
  • Biochemical Screening Tests
  • Others

By Application Outlook (Revenue - USD Billion, 2020-2034)

  • Monosomy
  • Trisomy
  • Microdeletion Syndrome
  • Others

By End-Use Outlook (Revenue - USD Billion, 2020-2034)

  • Diagnostic Centers
  • Hospitals and Clinics
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Australia
  • Malaysia
  • Vietnam
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of the Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Non-Invasive Prenatal Testing (NIPT) Market Insights

  • 4.1. Non-Invasive Prenatal Testing (NIPT) Market - Application Snapshot
  • 4.2. Non-Invasive Prenatal Testing (NIPT) Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising technological advancements in sequencing technologies and bioinformatics
      • 4.2.1.2. Rise in Maternal Age
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Application of NIPT for sex selection on non-medical backgrounds is prohibited in some countries.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Non-Invasive Prenatal Testing (NIPT) Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
  • 5.3. 0-12 weeks
    • 5.3.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by 0-12 weeks, by Region, 2020-2034 (USD Billion)
  • 5.4. 13-24 weeks
    • 5.4.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by 13-24 weeks, by Region, 2020-2034 (USD Billion)
  • 5.5. 25-36 weeks
    • 5.5.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by 25-36 weeks, by Region, 2020-2034 (USD Billion)

6. Global Non-Invasive Prenatal Testing (NIPT) Market, by Component

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
  • 6.3. Consumables
    • 6.3.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Consumables, by Region, 2020-2034 (USD Billion)
  • 6.4. Instruments
    • 6.4.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Instruments, by Region, 2020-2034 (USD Billion)
  • 6.5. Software
    • 6.5.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Software, by Region, 2020-2034 (USD Billion)
  • 6.6. Services
    • 6.6.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Services, by Region, 2020-2034 (USD Billion)

7. Global Non-Invasive Prenatal Testing (NIPT) Market, by Method

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
  • 7.3. Cell-Free DNA in Maternal Plasma Tests
    • 7.3.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Cell-Free DNA in Maternal Plasma Tests, by Region, 2020-2034 (USD Billion)
  • 7.4. Ultrasound Detection
    • 7.4.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Ultrasound Detection, by Region, 2020-2034 (USD Billion)
  • 7.5. Biochemical Screening Tests
    • 7.5.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Biochemical Screening Tests, by Region, 2020-2034 (USD Billion)
  • 7.6. Others
    • 7.6.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Non-Invasive Prenatal Testing (NIPT) Market, by Application

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
  • 8.3. Monosomy
    • 8.3.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Monosomy, by Region, 2020-2034 (USD Billion)
  • 8.4. Trisomy
    • 8.4.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Trisomy, by Region, 2020-2034 (USD Billion)
  • 8.5. Microdeletion Syndrome
    • 8.5.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Microdeletion Syndrome, by Region, 2020-2034 (USD Billion)
  • 8.6. Other
    • 8.6.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Other, by Region, 2020-2034 (USD Billion)

9. Global Non-Invasive Prenatal Testing (NIPT) Market, by End Use

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
  • 9.3. Diagnostic Centers
    • 9.3.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Diagnostic Centers, by Region, 2020-2034 (USD Billion)
  • 9.4. Hospitals and Clinics
    • 9.4.1. Global Non-Invasive Prenatal Testing (NIPT) Market, by Hospitals and Clinics, by Region, 2020-2034 (USD Billion)

10. Global Non-Invasive Prenatal Testing (NIPT) Market, by Geography

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Non-Invasive Prenatal Testing (NIPT) Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 10.3. Non-Invasive Prenatal Testing (NIPT) Market - North America
    • 10.3.1. North America: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
    • 10.3.2. North America: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
    • 10.3.3. North America: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
    • 10.3.4. North America: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
    • 10.3.5. North America: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.3.7. Non-Invasive Prenatal Testing (NIPT) Market - U.S.
      • 10.3.7.1. U.S.: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.3.7.2. U.S.: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.3.7.3. U.S.: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.3.7.4. U.S.: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.3.7.5. U.S.: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.3.8. Non-Invasive Prenatal Testing (NIPT) Market - Canada
      • 10.3.8.1. Canada: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.3.8.2. Canada: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.3.8.3. Canada: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.3.8.4. Canada: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.3.8.5. Canada: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
  • 10.4. Non-Invasive Prenatal Testing (NIPT) Market - Europe
    • 10.4.1. Europe: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
    • 10.4.2. Europe: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
    • 10.4.3. Europe: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
    • 10.4.4. Europe: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
    • 10.4.5. Europe: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.4.6. Non-Invasive Prenatal Testing (NIPT) Market - UK
      • 10.4.6.1. UK: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.4.6.2. UK: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.4.6.3. UK: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.4.6.4. UK: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.4.6.5. UK: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.4.7. Non-Invasive Prenatal Testing (NIPT) Market - France
      • 10.4.7.1. France: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.4.7.2. France: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.4.7.3. France: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.4.7.4. France: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.4.7.5. France: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.4.8. Non-Invasive Prenatal Testing (NIPT) Market - Germany
      • 10.4.8.1. Germany: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.4.8.2. Germany: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.4.8.3. Germany: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.4.8.4. Germany: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.4.8.5. Germany: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.4.9. Non-Invasive Prenatal Testing (NIPT) Market - Italy
      • 10.4.9.1. Italy: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.4.9.2. Italy: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.4.9.3. Italy: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.4.9.4. Italy: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.4.9.5. Italy: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.4.10. Non-Invasive Prenatal Testing (NIPT) Market - Spain
      • 10.4.10.1. Spain: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.4.10.2. Spain: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.4.10.3. Spain: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.4.10.4. Spain: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.4.10.5. Spain: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.4.11. Non-Invasive Prenatal Testing (NIPT) Market - Netherlands
      • 10.4.11.1. Netherlands: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.4.11.2. Netherlands: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.4.11.3. Netherlands: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.4.11.4. Netherlands: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.4.11.5. Netherlands: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.4.12. Non-Invasive Prenatal Testing (NIPT) Market - Russia
      • 10.4.12.1. Russia: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.4.12.2. Russia: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.4.12.3. Russia: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.4.12.4. Russia: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.4.12.5. Russia: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.4.13. Non-Invasive Prenatal Testing (NIPT) Market - Rest of Europe
      • 10.4.13.1. Rest of Europe: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.4.13.2. Rest of Europe: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.4.13.3. Rest of Europe: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.4.13.4. Rest of Europe: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.4.13.5. Rest of Europe: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
  • 10.5. Non-Invasive Prenatal Testing (NIPT) Market - Asia Pacific
    • 10.5.1. Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
    • 10.5.2. Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
    • 10.5.3. Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
    • 10.5.4. Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
    • 10.5.5. Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.5.6. Non-Invasive Prenatal Testing (NIPT) Market - China
      • 10.5.6.1. China: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.5.6.2. China: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.5.6.3. China: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.5.6.4. China: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.5.6.5. China: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.5.7. Non-Invasive Prenatal Testing (NIPT) Market - India
      • 10.5.7.1. India: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.5.7.2. India: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.5.7.3. India: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.5.7.4. India: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.5.7.5. India: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.5.8. Non-Invasive Prenatal Testing (NIPT) Market - Malaysia
      • 10.5.8.1. Malaysia: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.5.8.2. Malaysia: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.5.8.3. Malaysia: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.5.8.4. Malaysia: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.5.8.5. Malaysia: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.5.9. Non-Invasive Prenatal Testing (NIPT) Market - Japan
      • 10.5.9.1. Japan: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.5.9.2. Japan: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.5.9.3. Japan: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.5.9.4. Japan: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.5.9.5. Japan: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.5.10. Non-Invasive Prenatal Testing (NIPT) Market - Indonesia
      • 10.5.10.1. Indonesia: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.5.10.2. Indonesia: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.5.10.3. Indonesia: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.5.10.4. Indonesia: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.5.10.5. Indonesia: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.5.11. Non-Invasive Prenatal Testing (NIPT) Market - South Korea
      • 10.5.11.1. South Korea: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.5.11.2. South Korea: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.5.11.3. South Korea: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.5.11.4. South Korea: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.5.11.5. South Korea: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.5.12. Non-Invasive Prenatal Testing (NIPT) Market - Australia
      • 10.5.12.1. Australia: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.5.12.2. Australia: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.5.12.3. Australia: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.5.12.4. Australia: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.5.12.5. Australia: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.5.13. Non-Invasive Prenatal Testing (NIPT) Market - Rest of Asia Pacific
      • 10.5.13.1. Rest of Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.5.13.2. Rest of Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.5.13.3. Rest of Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.5.13.4. Rest of Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.5.13.5. Rest of Asia Pacific: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
  • 10.6. Non-Invasive Prenatal Testing (NIPT) Market - Middle East & Africa
    • 10.6.1. Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
    • 10.6.2. Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
    • 10.6.3. Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
    • 10.6.4. Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
    • 10.6.5. Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.6.6. Non-Invasive Prenatal Testing (NIPT) Market - Saudi Arabia
      • 10.6.6.1. Saudi Arabia: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.6.6.2. Saudi Arabia: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.6.6.3. Saudi Arabia: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.6.6.4. Saudi Arabia: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.6.6.5. Saudi Arabia: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.6.7. Non-Invasive Prenatal Testing (NIPT) Market - UAE
      • 10.6.7.1. UAE: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.6.7.2. UAE: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.6.7.3. UAE: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.6.7.4. UAE: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.6.7.5. UAE: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.6.8. Non-Invasive Prenatal Testing (NIPT) Market - Israel
      • 10.6.8.1. Israel: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.6.8.2. Israel: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.6.8.3. Israel: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.6.8.4. Israel: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.6.8.5. Israel: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.6.9. Non-Invasive Prenatal Testing (NIPT) Market - South Africa
      • 10.6.9.1. South Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.6.9.2. South Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.6.9.3. South Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.6.9.4. South Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.6.9.5. South Africa: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.6.10. Non-Invasive Prenatal Testing (NIPT) Market - Rest of Middle East & Africa
      • 10.6.10.1. Rest of Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.6.10.2. Rest of Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.6.10.3. Rest of Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.6.10.4. Rest of Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.6.10.5. Rest of Middle East & Africa: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
  • 10.7. Non-Invasive Prenatal Testing (NIPT) Market - Latin America
    • 10.7.1. Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
    • 10.7.2. Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
    • 10.7.3. Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
    • 10.7.4. Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
    • 10.7.5. Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.7.6. Non-Invasive Prenatal Testing (NIPT) Market - Mexico
      • 10.7.6.1. Mexico: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.7.6.2. Mexico: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.7.6.3. Mexico: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.7.6.4. Mexico: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.7.6.5. Mexico: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.7.7. Non-Invasive Prenatal Testing (NIPT) Market - Brazil
      • 10.7.7.1. Brazil: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.7.7.2. Brazil: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.7.7.3. Brazil: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.7.7.4. Brazil: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.7.7.5. Brazil: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.7.8. Non-Invasive Prenatal Testing (NIPT) Market - Argentina
      • 10.7.8.1. Argentina: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.7.8.2. Argentina: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.7.8.3. Argentina: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.7.8.4. Argentina: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.7.8.5. Argentina: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)
    • 10.7.9. Non-Invasive Prenatal Testing (NIPT) Market - Rest of Latin America
      • 10.7.9.1. Rest of Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by Gestation Period, 2020-2034 (USD Billion)
      • 10.7.9.2. Rest of Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by Component, 2020-2034 (USD Billion)
      • 10.7.9.3. Rest of Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by Method, 2020-2034 (USD Billion)
      • 10.7.9.4. Rest of Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2020-2034 (USD Billion)
      • 10.7.9.5. Rest of Latin America: Non-Invasive Prenatal Testing (NIPT) Market, by End Use, 2020-2034 (USD Billion)

11. Competitive Landscape

  • 11.1. Expansion and Acquisition Analysis
    • 11.1.1. Expansion
    • 11.1.2. Acquisitions
  • 11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

  • 12.1. Agilent Technologies, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Benchmarking
    • 12.1.4. Recent Development
  • 12.2. Centogene N.V
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Benchmarking
    • 12.2.4. Recent Development
  • 12.3. Eurofins LifeCodexx GmbH
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Benchmarking
    • 12.3.4. Recent Development
  • 12.4. F; Hoffmann-La Roche Ltd
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Benchmarking
    • 12.4.4. Recent Development
  • 12.5. Illumina, Inc
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Benchmarking
    • 12.5.4. Recent Development
  • 12.6. Laboratory Corp. of America Holdings
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Benchmarking
    • 12.6.4. Recent Development
  • 12.7. MedGenome Labs Ltd
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Benchmarking
    • 12.7.4. Recent Development
  • 12.8. Myriad Women's Health, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Benchmarking
    • 12.8.4. Recent Development
  • 12.9. Natera, Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Benchmarking
    • 12.9.4. Recent Development
  • 12.10. Progenity, Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Benchmarking
    • 12.10.4. Recent Development
  • 12.11. Qiagen
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Benchmarking
    • 12.11.4. Recent Development
  • 12.12. Quest Diagnostics, Inc.
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Benchmarking
    • 12.12.4. Recent Development
  • 12.13. Thermo Fisher Scientific, Inc.
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Benchmarking
    • 12.13.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦